(160) Targeted Lipid Nanoparticles for Delivery of Gene Editing Technology to the Pulmonary Vasculature

Introduction: In recent years, lipid nanoparticles (LNPs) have emerged as a versatile drug delivery system due to their ability to encapsulate therapeutic nucleic acids (1). When injected intravenously, most LNPs accumulate in the liver, limiting their delivery to other organs (2). This restricts the potential application of LNPs to treat cell-type specific diseases, such as pulmonary arterial hypertension (PAH). PAH occurs when pulmonary arterioles are narrowed, often due to overactive serotonin growth factor production in pulmonary artery endothelial cells (PAECs) (3).